UNLIMITED FREE
ACCESS
TO THE WORLD'S BEST IDEAS

SUBMIT
Already a GlobalSpec user? Log in.

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

Customize Your GlobalSpec Experience

Finish!
Privacy Policy

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

NATO - STANAG 2242

POLICY FOR THE CHEMOPROPHYLAXIS AND IMMUNOTHERAPY OF NATO PERSONNEL AGAINST BIOLOGICAL WARFARE AGENTS

active, Most Current
Organization: NATO
Publication Date: 10 May 2005
Status: active
Page Count: 10
scope:

The aim of this agreement is to develop a unified approach in NATO doctrine and policy in the use of chemoprophylaxis and immunotherapy by NATO personnel against Biological Warfare (BW) agents that cause infectious disease.

Document History

STANAG 2242
May 10, 2005
POLICY FOR THE CHEMOPROPHYLAXIS AND IMMUNOTHERAPY OF NATO PERSONNEL AGAINST BIOLOGICAL WARFARE AGENTS
The aim of this agreement is to develop a unified approach in NATO doctrine and policy in the use of chemoprophylaxis and immunotherapy by NATO personnel against Biological Warfare (BW) agents that...

References

Advertisement